Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated
Read More
More than 100,000 people in Australia live with Parkinson’s—a central nervous system disorder affecting one’s movement and mood. It is a progressive disorder which currently has no cure and few treatments. However, researchers at Parkinson’s UK have a new reason to hope. They are investigating whether early detection and treatment of certain sleeping disorders might
Read More
This morning’s announcement may have surprised many investors following the Pharmaxis (ASX: PXS) story because where on earth does Parkinson’s fit into the equation alongside cancer, skin scarring and cystic fibrosis? Unpacking the Pharmaxis investment case reveals an agile company with more than one trick up their sleeves, keeping business buoyant whilst other biotechs list
Read More
Seven to ten years. That’s how long someone diagnosed with multiple system atrophy (MSA) has to live from when symptoms first appear. The progressive disease results in the gradual functional decline of the body’s involuntary functions such as blood pressure, breathing, bladder function and motor control. Often confused with Parkinson’s which is characterised by the
Read More